Aviron
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Aviron - overview
Location
Mountain View, CA, US
Primary Industry
Biotechnology
About
Aviron is a biotechnology company specializing in innovative therapeutic solutions. It focuses on developing and commercializing treatments that address unmet medical needs across various therapeutic areas. Aviron operates as a biotechnology firm that develops therapies for specific health challenges. Founded in Mountain View, US, the company has engaged in strategic changes since its inception.
On February 1, 2001, Aviron raised USD 188. 5 mn through an IPO by selling 4 million common shares at USD 50 each. In December 2001, Aviron merged with MedImmune, Inc. for approximately USD 1.
5 billion, valued at USD 47. 41 per share. The current CEO is known for previous entrepreneurial ventures, although specific details of these ventures are not available. Aviron's core offerings focus on delivering innovative therapeutic products designed to improve patient outcomes in healthcare.
The company provides high-quality healthcare solutions aimed at both B2B clients, including healthcare providers and institutions, and direct-to-consumer sales for individual patients. Their offerings are tailored to address diverse medical needs, with products that facilitate effective treatment protocols and improve patient experiences, thereby contributing to health management. In the most recent financial year, Aviron reported a revenue of USD 32. 24 mn, while the EBITDA for the same period was USD -63.
93 mn, indicating operational challenges despite generating significant sales. Aviron's growth strategy includes launching several new therapeutic products aimed at addressing critical medical conditions, with specific release dates to be announced. The company plans to expand its market presence in North America and Europe by targeting specific segments within these regions. The funds raised during the IPO in February 2001, amounting to USD 188.
5 mn, will be utilized to support the development of new therapies and to enhance operational capabilities as the company seeks to establish a stronger foothold in the biotech sector.
Current Investors
Ridgeway Investment, Acqua Wellington Asset Management
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Epidemiology
Website
www.aviron.com
Company Stage
PIPE
Total Amount Raised
Subscriber access only
Aviron - employee data
Aviron - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chairman of the Board | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.